Prevalence of overweight/obesity in Chinese children

Jian-Meng Liu1, Rongwei Ye, Song Li

  • 1Institute of Reproductive and Child Health and National Center for Maternal and Infant Health, Peking University Health Science Center, Beijing, People's Republic of China. liujm@ncmih.bjmu.edu.cn

Insights

In 2000, 7.4% of Chinese children aged 3.5-6.4 were overweight or obese, with higher rates in girls and northern rural areas. Adiposity rebound occurred after 6.5 years, indicating a later onset than in Western countries.

Area of Science:

  • Pediatric Endocrinology
  • Public Health Nutrition
  • Epidemiology

Background:

  • Childhood overweight and obesity are significant global health concerns.
  • Understanding prevalence and risk factors is crucial for targeted interventions.
  • Adiposity rebound age is a key indicator of long-term weight trajectory.

Purpose of the Study:

  • To determine the prevalence of overweight/obesity in Chinese children in 2000 by area, age, and gender.
  • To investigate the age of adiposity rebound using Body Mass Index (BMI) in Chinese children.

Main Methods:

  • A cross-sectional study involving 262,738 children aged 3.5-6.4 years across 26 Chinese counties/cities.
  • Standardized measurements of height and weight collected from March to July 2000.
  • International age- and gender-specific BMI cut-off points and multiple logistic regression analysis were employed.

Main Results:

  • The overall prevalence of overweight/obesity was 7.4% (19,390 children).
  • Girls exhibited higher odds of being overweight/obese (OR=1.14) compared to boys.
  • Higher prevalence was observed in northern rural areas (OR=2.58) and among younger children (aged 3.5-5.5 years).

Conclusions:

  • Childhood overweight/obesity rates in China in 2000 mirrored those in Great Britain or the U.S. in earlier decades.
  • The age of adiposity rebound in Chinese children was determined to be over 6.5 years.
  • Findings highlight regional and gender disparities in childhood obesity and a later adiposity rebound pattern.
Abstract

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.